全文获取类型
| 收费全文 | 3161730篇 |
| 免费 | 297163篇 |
| 国内免费 | 40079篇 |
专业分类
| 耳鼻咽喉 | 41629篇 |
| 儿科学 | 91104篇 |
| 妇产科学 | 74525篇 |
| 基础医学 | 506187篇 |
| 口腔科学 | 82920篇 |
| 临床医学 | 300939篇 |
| 内科学 | 533751篇 |
| 皮肤病学 | 86477篇 |
| 神经病学 | 264353篇 |
| 特种医学 | 122183篇 |
| 外国民族医学 | 333篇 |
| 外科学 | 478465篇 |
| 综合类 | 156859篇 |
| 现状与发展 | 108篇 |
| 一般理论 | 2095篇 |
| 预防医学 | 251830篇 |
| 眼科学 | 74603篇 |
| 药学 | 233872篇 |
| 447篇 | |
| 中国医学 | 34186篇 |
| 肿瘤学 | 162106篇 |
出版年
| 2022年 | 30015篇 |
| 2021年 | 71612篇 |
| 2020年 | 50378篇 |
| 2019年 | 72970篇 |
| 2018年 | 83928篇 |
| 2017年 | 67571篇 |
| 2016年 | 72076篇 |
| 2015年 | 92461篇 |
| 2014年 | 130214篇 |
| 2013年 | 193268篇 |
| 2012年 | 102141篇 |
| 2011年 | 101612篇 |
| 2010年 | 134055篇 |
| 2009年 | 134876篇 |
| 2008年 | 78303篇 |
| 2007年 | 77506篇 |
| 2006年 | 88172篇 |
| 2005年 | 82711篇 |
| 2004年 | 78239篇 |
| 2003年 | 69043篇 |
| 2002年 | 57251篇 |
| 2001年 | 86737篇 |
| 2000年 | 78423篇 |
| 1999年 | 83040篇 |
| 1998年 | 66594篇 |
| 1997年 | 64743篇 |
| 1996年 | 61197篇 |
| 1995年 | 56559篇 |
| 1994年 | 50187篇 |
| 1993年 | 46402篇 |
| 1992年 | 51715篇 |
| 1991年 | 47999篇 |
| 1990年 | 44535篇 |
| 1989年 | 44811篇 |
| 1988年 | 41256篇 |
| 1987年 | 39906篇 |
| 1986年 | 37530篇 |
| 1985年 | 38107篇 |
| 1984年 | 37399篇 |
| 1983年 | 35024篇 |
| 1982年 | 37712篇 |
| 1981年 | 35824篇 |
| 1980年 | 33781篇 |
| 1979年 | 28267篇 |
| 1978年 | 27484篇 |
| 1977年 | 26231篇 |
| 1976年 | 23308篇 |
| 1975年 | 21306篇 |
| 1974年 | 20262篇 |
| 1973年 | 19306篇 |
排序方式： 共有10000条查询结果，搜索用时 31 毫秒
931.
932.
933.
Victoria A. Chang Dawn M. Meyer Brett C. Meyer 《Journal of stroke and cerebrovascular diseases》2019,28(1):163-166
Background
Acute stroke codes may be activated for anisocoria, but how often these codes lead to a final stroke diagnosis or alteplase treatment is unknown. The purpose of this study was to assess the frequency of anisocoria in stroke codes that ultimately resulted in alteplase administration.Methods
We retrospectively assessed consecutive alteplase-treated patients from a prospectively-collected stroke registry between February 2015 and July 2018. Based on the stroke code exam, patients were categorized as having isolated anisocoria [A+(only)], anisocoria with other findings [A+(other)], or no anisocoria [A?]. Baseline demographics, stroke severity, alteplase time metrics, and outcomes were also collected.Results
Ninety-six patients received alteplase during the study period. Of the 94 who met inclusion criteria, there were 0 cases of A+(only). There were 9 cases of A+(other) (9.6%). A+(other) exhibited higher baseline National Institutes of Health (NIH) Stroke Scale scores compared to A? (17 versus 7; P?=?.0003), and no additional differences in demographics or alteplase time metrics. Final stroke diagnosis and other outcome measures were no different between A+(other) and A?. Of the A+ patients without pre-existing anisocoria, 5 of 6 (83%) had posterior circulation events or diffuse subarachnoid hemorrhage.Conclusions
In this exploratory analysis, zero patients with isolated anisocoria received alteplase treatment. Anisocoria as a part of the neurologic presentation occurred in 10% of alteplase patients, and was strongly associated with a posterior circulation event. Therefore, we conclude that anisocoria has a higher likelihood of leading to alteplase treatment when identified in the presence of other neurologic deficits. 相似文献934.
Annals of Surgical Oncology - 相似文献
935.
936.
Jae Eun Choi Tyler Werbel Zhenping Wang Chia Chi Wu Tony L. Yaksh Anna Di Nardo 《Journal of dermatological science》2019,93(1):58-64
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献937.
938.
939.
Abdominal Radiology - 相似文献